London
· Delayed Price · Currency is GBP · Price in GBXAlliance Pharma Statistics
Total Valuation
Alliance Pharma has a market cap or net worth of GBP 231.09 million. The enterprise value is 326.07 million.
| Market Cap | 231.09M |
| Enterprise Value | 326.07M |
Important Dates
The next estimated earnings date is Friday, September 20, 2024.
| Earnings Date | Sep 20, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Alliance Pharma has 540.57 million shares outstanding. The number of shares has increased by 0.12% in one year.
| Shares Outstanding | 540.57M |
| Shares Change (YoY) | +0.12% |
| Shares Change (QoQ) | -0.24% |
| Owned by Insiders (%) | 0.13% |
| Owned by Institutions (%) | 75.30% |
| Float | 455.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 9.74 |
| PS Ratio | 1.28 |
| PB Ratio | 1.06 |
| P/FCF Ratio | 7.52 |
| PEG Ratio | 1.73 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.40, with an EV/FCF ratio of 10.62.
| EV / Earnings | -9.84 |
| EV / Sales | 1.80 |
| EV / EBITDA | 6.40 |
| EV / EBIT | 7.66 |
| EV / FCF | 10.62 |
Financial Position
The company has a current ratio of 2.57, with a Debt / Equity ratio of 53.89.
| Current Ratio | 2.57 |
| Quick Ratio | 1.83 |
| Debt / Equity | 53.89 |
| Debt / EBITDA | 2.30 |
| Debt / FCF | 3.82 |
| Interest Coverage | 4.26 |
Financial Efficiency
Return on equity (ROE) is -13.71% and return on invested capital (ROIC) is 7.21%.
| Return on Equity (ROE) | -13.71% |
| Return on Assets (ROA) | 5.76% |
| Return on Capital (ROIC) | 7.21% |
| Revenue Per Employee | 618,767 |
| Profits Per Employee | -113,479 |
| Employee Count | 292 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 3.03 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.29% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -14.29% |
| 50-Day Moving Average | 36.86 |
| 200-Day Moving Average | 37.67 |
| Relative Strength Index (RSI) | 74.39 |
| Average Volume (20 Days) | 1,328,505 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Alliance Pharma had revenue of GBP 180.68 million and -33.14 million in losses. Loss per share was -0.06.
| Revenue | 180.68M |
| Gross Profit | 105.02M |
| Operating Income | 42.56M |
| Pretax Income | -48.80M |
| Net Income | -33.14M |
| EBITDA | 50.23M |
| EBIT | 42.56M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 22.44 million in cash and 117.42 million in debt, giving a net cash position of -94.98 million or -0.18 per share.
| Cash & Cash Equivalents | 22.44M |
| Total Debt | 117.42M |
| Net Cash | -94.98M |
| Net Cash Per Share | -0.18 |
| Equity (Book Value) | 217.87M |
| Book Value Per Share | 0.40 |
| Working Capital | 63.53M |
Cash Flow
In the last 12 months, operating cash flow was 31.41 million and capital expenditures -696,000, giving a free cash flow of 30.71 million.
| Operating Cash Flow | 31.41M |
| Capital Expenditures | -696,000 |
| Free Cash Flow | 30.71M |
| FCF Per Share | 0.06 |
Margins
Gross margin is 58.12%, with operating and profit margins of 23.56% and -18.34%.
| Gross Margin | 58.12% |
| Operating Margin | 23.56% |
| Pretax Margin | -27.01% |
| Profit Margin | -18.34% |
| EBITDA Margin | 27.80% |
| EBIT Margin | 23.56% |
| FCF Margin | 17.00% |
Dividends & Yields
Alliance Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | 5.03% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.12% |
| Shareholder Yield | -0.12% |
| Earnings Yield | -14.35% |
| FCF Yield | 13.29% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |